Australia has committed to support global vaccination, with a primary focus on the Indo-Pacific region, through four channels:
The four channels are not completely independent. 40 out of the 60 million vaccine donations would be provided from Australia’s own supply, while the remaining 20 million will be procured and funded through the AU$523.2 million bilateral support and AU$100 QUAD Vaccine Partnership.
In April 2020, the WHO launched its Access to COVID-19 Tools (ACT) Accelerator which brings together various global health organisations to accelerate the development, production and equitable access to COVID-19 tests, treatments and vaccines. As part of this initiative, the WHO has also developed the ACT-Accelerator Commitment Tracker to report on funding commitments made by countries and organisations against ACT-Accelerator Pillar budgets through nine leading global health organisations (CEPI, Gavi, Therapeutics Accelerator, Unitaid, FIND, Global Fund, WHO, UNICEF, GFF).
This cooperation is organised around four pillars: diagnostics, therapeutics, vaccines and health system strengthening. The vaccines pillar is delivered through COVAX, which is a global vaccine sharing initiative co-led by the WHO, Gavi, and CEPI. The Gavi COVAX Advance Market Commitment (AMC) is a part of the initiative that supports access to vaccines for 92 eligible low- and middle-income countries.
As of 29 Oct 2021, the ACT-Accelerator had received total financial commitments of US$17.8 billion towards the 2020-21 budget, with a funding gap of US$15.4 billion. In the budget year from Oct 2021 to Sep 2022, ACT-Accelerator is seeking to raise grant funding of US$16.85 billion, with US$5.98 billion for vaccines (COVAX),US$4.73 billion for diagnostics, US$3.65 billion for health systems, and US$2.48 billion for therapeutics.
Altogether, Australia has committed US$216 million to ACT-Accelerator, about 1% of a total of US$21.6 billion from government donors. Australia’s ranking in total funding among government donors is currently 15th out of 58. US$200 million of Australia’s total funding commitments is provided to COVAX, which is ACT-Accelerator’s vaccines pillar. The breakdown of Australia’s funding commitments can be found in the charts below.
In addition to funding, Australia has pledged to offer at least 10 million vaccine doses to the COVAX AMC. This donation has not been reflected in either the ACT-Accelerator tracker or UNICEF’s COVID-19 Vaccine Market Dashboard. As explained in this blog, Australia has made its vaccine contributions mainly through bilateral and regional efforts.
Australia’s regional and bilateral contributions include bilateral donations of vaccine doses, AU$523.5 VAHSI “end-to-end” support, and AU$100 million QUAD Vaccine Partnership commitments.
According to the Australian Government’s Vaccine Access for the Indo-Pacific reporting, as at 18 October 2022 Australia has shared a total of 49.8 million vaccine doses in the Indo-Pacific region, meeting over eighty percent of its goal of sharing 60 million doses by the end of 2022. Vaccines delivered through the QUAD Vaccine Partnership by Australia and other partners can be found in this Dashboard.
Among the recipients of those 49.8 million donated vaccines, Vietnam is the biggest recipient with 25.3 million doses, followed by Indonesia, the Philippines, and Cambodia. Overall, Southeast Asian countries have received a total of 45.7 million doses, while Pacific countries and Timor-Leste share the rest (4.1 million).
UNICEF’s COVID-19 Vaccine Market Dashboard tracks globally reported vaccine donations and deliveries. According to its reporting, Australia ranks 8th in vaccine donations and 9th in vaccine deliveries among government donors.
To learn more about Australia’s COVID funding and vaccine contributions, check WHO's ACT-Accelerator Commitment Tracker, the Economist’s COVID-19 Health Funding Tracker, UNICEF’s COVID-19 Vaccine Market Dashboard, Indo-Pacific Centre for Health Security’s Vaccine Access for the Indo-Pacific, QUAD country COVID-19 response in Indo-Pacific region, and Think Global Health.